Researchers at University College London have identified a molecular mechanism the human body uses to shut down acute inflammation, and they showed that an existing drug compound can amplify that process. In a study of 48 healthy volunteers, the team mapped how a class of fat-derived signaling molecules called epoxy-oxylipins steer immune cells away from prolonged inflammatory states, offering faster pain relief and reduced immune cell persistence. The findings, published in Nature Communications, point toward a strategy that works with the body’s own resolution signals rather than simply suppressing immune activity.
Why a built-in inflammation brake matters right now
Most anti-inflammatory drugs, from ibuprofen to corticosteroids, work by blocking the onset of inflammation. That approach can dampen symptoms, but it also interferes with the immune response the body needs to fight infection and heal tissue. The UCL study takes a different angle: instead of preventing inflammation from starting, the researchers asked what the body does to stop it once the job is done.
The answer centers on an enzyme called soluble epoxide hydrolase, or sEH. Under normal conditions, sEH breaks down protective epoxy-oxylipins in the blood. When the researchers blocked sEH with the compound GSK2256294, levels of one oxylipin in particular, 12,13-EpOME, rose sharply. That molecule redirected monocytes, a type of white blood cell central to inflammation, toward a resolution-friendly state. The practical result was that volunteers experienced faster pain resolution and showed lower counts of intermediate monocytes, the subset most associated with lingering tissue damage.
A key design choice makes the study especially informative. The team split its 48 volunteers into two arms of 24, testing GSK2256294 as either a prophylactic dose given before inflammation was triggered or a therapeutic dose given afterward. Both approaches targeted the same enzyme, but the timing difference matters. When sEH was inhibited before the inflammatory challenge, 12,13-EpOME levels were already elevated as monocytes began arriving at the injury site. That early presence appears to alter the differentiation trajectory of those cells before peak inflammation takes hold, producing a distinct resolution signature compared with later dosing. If confirmed in larger trials, the distinction could shape how and when future sEH-targeting drugs are administered.
Oxylipin dynamics and the UCL volunteer experiments
To trigger a controlled, short-lived inflammatory response, the researchers injected UV-killed E. coli into the forearms of volunteers and then tracked symptoms and blood biomarkers over time. The use of dead bacteria ensured a genuine immune reaction without the risk of actual infection, giving the team a clean window into how epoxy-oxylipins directed monocyte fate during resolution.
Study author Olivia Bracken and senior investigator Derek Gilroy led the work, which combined lipid profiling with single-cell immune phenotyping to show that sEH inhibition did not merely reduce inflammation but actively steered monocytes toward a pro-resolution identity. By sampling blood at multiple time points, the team could follow how distinct monocyte subsets rose and fell as 12,13-EpOME levels changed, linking lipid signatures to cellular behavior and clinical symptoms such as pain and local swelling.
GSK2256294 itself is not a new molecule. It was originally developed by GlaxoSmithKline and has already been through a phase-1 human pharmacokinetics and safety study, which established dose-exposure relationships and a manageable adverse-event profile. Separate clinical work tested the compound for vascular endpoints in smokers and patients with chronic obstructive pulmonary disease, confirming that it engages the sEH target in living patients and alters epoxy-lipid biology across different disease contexts. The new Nature Communications paper builds on that platform by using detailed lipidomics and immune profiling to connect target engagement to a measurable resolution phenotype.
That prior safety record is significant because it shortens the path to clinical testing of the inflammation-resolution concept. Rather than starting from scratch with a novel compound, researchers can build on existing human data to design trials focused specifically on whether boosting epoxy-oxylipins resolves chronic inflammatory conditions such as rheumatoid arthritis, atherosclerosis, or inflammatory bowel disease. The ability to repurpose a compound with known pharmacology could shave years off the typical development timeline for an entirely new anti-inflammatory drug.
Open questions about sEH inhibition and chronic disease
The UCL study was conducted entirely in healthy volunteers experiencing a brief, artificially induced inflammatory episode. Whether the same oxylipin-driven resolution mechanism operates in patients with chronic, self-sustaining inflammation has not been tested. Diseases like rheumatoid arthritis involve feedback loops, tissue remodeling, and immune memory that a single forearm injection of dead bacteria cannot replicate. In such settings, inflammatory cells and stromal tissue may be locked into maladaptive states that are harder to reprogram with a short burst of epoxy-oxylipins.
Detailed head-to-head clinical outcome data comparing the prophylactic and therapeutic dosing arms, such as granular pain scores or swelling measurements over time, have so far been presented only as summarized figures in the published paper. Independent researchers will need access to patient-level time-series data to evaluate whether the monocyte-resolution signatures differ meaningfully between the two dosing windows or whether both converge on similar endpoints once inflammation subsides. Long-term safety data after repeated GSK2256294 dosing in an acute inflammation model also remain unreported, leaving questions about how the enzyme blockade might behave in patients who require ongoing treatment.
Another open question concerns the broader network of lipids and immune mediators that interact with 12,13-EpOME. The current work highlights one epoxy-oxylipin as a key driver of resolution, but sEH controls an entire family of related molecules derived from omega-3 and omega-6 fatty acids. Enhancing some of these lipids while suppressing others could have mixed effects, especially in organs such as the heart, lungs, and brain where lipid signaling is tightly regulated. Future studies will need to map these pathways in more detail and determine whether selective modulation of specific oxylipins is preferable to a broad sEH inhibition strategy.
There is also the issue of patient heterogeneity. Genetic variation in sEH, baseline lipid profiles, diet, and concurrent medications could all shape how individuals respond to GSK2256294 or similar compounds. In chronic disease cohorts, researchers may find subgroups who benefit strongly from epoxy-oxylipin boosting and others who see little change in symptoms or even unintended side effects. Stratified trial designs that incorporate genomics and metabolomics from the outset will be crucial to identify which patients are most likely to gain from this resolution-focused approach.
For patients living with conditions driven by unresolved inflammation, the practical takeaway is that a drug compound with existing human safety data could, in principle, be repurposed to help the immune system stand down once its work is complete, rather than simply blunting inflammatory signals across the board. By amplifying the body’s own molecular brakes, therapies based on sEH inhibition and epoxy-oxylipins might one day offer a way to cool chronic inflammation while preserving the capacity to fight infection and repair tissue. The UCL findings do not yet deliver that treatment, but they provide a mechanistic roadmap and a ready-made clinical candidate to test whether harnessing resolution biology can change the course of inflammatory disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
